Aniracetam for treatment of patients with progressive supranuclear palsy

European Neurology

Volumn 37, Issue 3, 1997, Pages 195-198

  Nagasaka, Takamura ^a   Togashi, Shinji ^a   Amino, Akiyoshi ^a   Nitta, Kiyoaki ^a   Shindo, Kazumasa ^a   Shiozawa, Zenji ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANIRACETAM; MUSCARINIC RECEPTOR; TRIHEXYPHENIDYL;

AGED; ARTICLE; BASAL GANGLION; BRAIN ATROPHY; CASE REPORT; DRUG EFFICACY; FEMALE; FRONTAL LOBE; GAIT DISORDER; GLUCOSE UTILIZATION; HUMAN; INTELLECT; MALE; MOTOR PERFORMANCE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RETICULAR FORMATION;

AGED; DYSTONIA; ELECTROENCEPHALOGRAPHY; EYE MOVEMENTS; FEMALE; GAIT; HUMANS; MALE; PYRROLIDINONES; SUPRANUCLEAR PALSY, PROGRESSIVE; WRITING;

EID: 0030939048     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000117437     Document Type: Article

References (19)

1. Steele JC. Richardson JC, Olszewski J: Progressive supranuclear palsy. Arch Neurol 1964;10:333-359.
2. Jackson JA, Jankovic J, Ford J: Progressive supranuclear palsy: Clinical features and response to treatment in 16 patients. Ann Neurol 1983; 13: 273-278.
3. Onodera J, Nomura H, Okita H, Takase S: A case with progressive supranuclear palsy showing efficacy to L-threo-3.4-dihydroxyphenylscrine. Shinkei Chiryo 1991;8:469-471.
4. Cole DG. Growdon JH: Therapy for progressive supranuclear palsy, past and future. J Neural Transm 1994;42:283-290.
5. Kvale JN: Amitriptyline in the management of progressive supranuclear palsy. Arch Neurol 1982:39:387-388.
6. Katoh E, Takahashi S, Abe T, Kawamorita A, Tohgi H: A case with progressive supranuclear palsy presenting rigidity, nuchal dystonia and autonomic nervous symptoms which showed efficacy to trazodone, an inhibitor against re-uptake of serotonin. Rinsho Shinkei 1994;34:1013-1017.
7. Himori N: Modifying activity of aniracetam to synaptic efficiencies by glutamic acid and acetylcholine system. Yakuri To Chiryo 1993;21:335-341.
8. Landwehrmeyer B, Palacios JM: Alteration of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy. J Neural Transm 1994:42:229-246.
9. Kish SJ, Chang LJ. Mirchandani L, Shannak K, Hornykiewicz O: Progressive supranuclear palsy: Relationship between extrapyramidal disturbances. dementia and brain neurotransmitter markers. Ann Neurol 1985; 18:530-536.
10. Whitehousc PJ, Martino AM, Marcus KA, Zweig RM, Singer HS, Price DL, Kellar KJ: Reduction in acetylcholine and nicotine binding in several degenerative diseases. Arch Neurol 1988:45:722-724.
11. Ruberg M, Javoi-Agid F, Hirsch E, Scatton B, L'Heureux R, Hauw JJ. Duyckaerts C, Gray F, Morel-Maroger A, Rascol A, Serdaru M, Agid Y: Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 1985;18:523-529.
12. Zweig RM, Whitehouse PJ, Casanova MF, Walker LC, Jankel WR, Price DL: Loss of pedunculopontine neurons in progressive supranuclear palsy. Ann Neurol 1987;22:18-25.
13. Hirsch EG. Graybiel AM, Duyckaerts C, Javoy-Agid F: Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson's disease and progressive supranuclear palsy. Proc Natl Acad Sci USA 1987.84:5976-5980.
14. Kimura T, Nakamura S, Kawamata T, Akiguchi I, Kamcyama M, Yasuhara O: Lesions of cholinergic nerves in human brainstem (pedunculopontinc tegmental nucleus). Shinkeibyori 1987;(suppl 7): 153.
15. Kubota A, Hayashi T, Sakagami T, Watanabe A, Nakamura K: Scopolamine model of retrograde amnesia: its prevention and relevant cerebral nuclei involved: in Saito S, Yamagata T (eds): Learning and Memory; Drugs as Reinforcer. Amsterdam, Excerpta Medica, 1983. pp 96-118.
16. Parnetti L, Bartorelli L, Bonaiuto S, Cucinotta D, Cuzzupoli M, Erminio F, Maggioni M, Marini G, Paciaroni E, Pedrazzi F, Peruzza M, Senin U: Aniracetam (Ro 13-5057) for the treatment of senile dementia of Alzheimer's type(SDAT): results of a multicenter clinical study. Dementia 1991:2:262-267.
17. Senin U, Abate G, Fieschi C, Gori G, Guala A, Marini G, Villardita C, Parnetti L: Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer's type (SDAT): results of a placebo-controlled multicenter clinical study. Eur Neuropsychopharmacol 1991;1:511-517.
18. Ebara T, Okumura K: A case supposed as striato-nigral degneration whose activity of daily living was improved by administration of aniracetam. Shikei Chiryo 1995;12:581-584.
19. Hornma S, Takei A, Fukazawa T, Hamada K, Hantada T: Treatment of Parkinson’s disease by aniracetam. Rohka To Shikkan 1995;8:96-99.